CMPX - Compass Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-10.37M

Cash

156.3M

Avg Qtr Burn

-10.57M

Short % of Float

2.06%

Insider Ownership

12.04%

Institutional Own.

70.84%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Biliary Tract Cancer, Cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-471 +/- KEYTRUDA® (pembrolizumab) Details Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-8371 (PD-1 x PD-L1) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.